Abstract |
Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor leukocyte transfusion is not available.
|
Authors | H Nagayama, S Takahashi, T Takahashi, K Ogami, K Ikebuchi, A Tojo, K Tani, S Asano |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 23
Issue 2
Pg. 183-5
(Jan 1999)
ISSN: 0268-3369 [Print] England |
PMID | 10197806
(Publication Type: Journal Article)
|
Chemical References |
- Adjuvants, Immunologic
- Interleukin-2
- Peptides
- poly(lysyl-(leucyl-poly-alanine))
|
Topics |
- Adjuvants, Immunologic
(therapeutic use)
- Adult
- Bone Marrow Transplantation
- Female
- Humans
- Interleukin-2
(therapeutic use)
- Leukemia, Monocytic, Acute
(therapy)
- Peptides
(therapeutic use)
|